索拉非尼对大鼠佐剂性关节炎的抑制作用

刘菲 龚永芳 王真珍 张晓明 邓雪飞 焦轶 黄学应*

doi:10.16098/j.issn.0529-1356.2017.02.012

PDF(705 KB)

解剖学报 ›› 2017, Vol. 48 ›› Issue (2) : 187-192. DOI: 10.16098/j.issn.0529-1356.2017.02.012

组织学胚胎学发育生物学

索拉非尼对大鼠佐剂性关节炎的抑制作用

刘菲龚永芳王真珍张晓明邓雪飞焦轶黄学应*

作者信息 +

Inhibition effect of sorafenib on adjuvant arthritis in rats

LIU Fei GONG Yong-fang WANG Zhen-zhen ZHANG Xiao-ming DENG Xue-fei JIAO Yi HUANG Xue-ying*

Author information +

文章历史 +

摘要

目的探讨索拉非尼对大鼠佐剂性关节炎(AA)的抑制作用。方法 36只雄性SD大鼠均分为6组，除正常组外，其余各组大鼠均制备AA模型。足容积法检测AA大鼠继发侧足爪容积；流式细胞术检测外周血CD4⁺及CD8⁺T细胞亚群的变化；免疫组织化学链霉卵白素-过氧化物酶法(SP)检测滑膜组织微血管密度(MVD)的改变。结果与模型组相比，索拉非尼组大鼠足爪容积下降，滑膜组织MVD减小，其中索拉非尼(20、40mg/kg)组可使外周血CD4⁺T细胞比例降低，CD8⁺T细胞比例增加，差异均有统计学意义(P<0.05)。结论索拉非尼具有抑制大鼠AA效应，该作用可能与索拉非尼引起AA大鼠外周血CD4⁺, CD8⁺T细胞亚群的偏移以及降低滑膜组织MVD有关。

Abstract

Objective To observe the inhibition effect of sorafenib on adjuvant arthritis in rats. Methods A total of 36 male SPF SD rats were divided into 6 groups and 0.1ml of the complete Freund’s adjuvant was subcutaneously injected into the left hind paw except the normal group. The volume of rat hind paw was measured. The CD4⁺ and CD8⁺T cell subsets of the peripheral blood were analyzed by flow cytometry. The microvessel density of synovial tissues was determined by immunohistochemical chain mildew avidin peroxidase enzymatic (SP) method. Results Compared with model group, the rats of sorafenib groups alleviated the volume of rat hind paw and reduced microvessel density. Sorafenib (20, 40mg/kg) groups decreased the percentage of CD4⁺T cell and increased the percentage of CD8⁺T cell at the same time. All the values were statistically significant(P<0.05). Conclusion Sorafenib can ameliorate adjuvant arthritis in rats, which effect may be related to sorafenib causing CD4+ and CD8+T cell subset of peripheral blood deviation and reducing microvessel density of synovial tissues.

导出引用

刘菲龚永芳王真珍张晓明邓雪飞焦轶黄学应. 索拉非尼对大鼠佐剂性关节炎的抑制作用[J]. 解剖学报. 2017, 48(2): 187-192 https://doi.org/10.16098/j.issn.0529-1356.2017.02.012

LIU Fei GONG Yong-fang WANG Zhen-zhen ZHANG Xiao-ming DENG Xue-fei JIAO Yi HUANG Xue-ying. Inhibition effect of sorafenib on adjuvant arthritis in rats[J]. Acta Anatomica Sinica. 2017, 48(2): 187-192 https://doi.org/10.16098/j.issn.0529-1356.2017.02.012

参考文献

［1］Zeng XF, Zhu SL, Tan ACh, et al. Disease burden and quality of life of rheumatoid arthritis in China:a systematic review［J］. Chinese Journal of Evidence-Based Medicine, 2013, 13(3):300-307.(in Chinese)

曾小峰, 朱松林, 谭爱春, 等. 我国类风湿关节炎疾病负担和生存质量研究的系统评价［J］. 中国循证医学杂志, 2013, 13(3):300-307.

［2］Broecker-Preuss M, Müller S, Britten M, et al. Sorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational status［J］. Bmc Cancer, 2014, 15(1):1-13.

［3］Kalathil SG, Lugade AA, Miller A, et al. PD-1+ and Foxp3+ T cell reduction correlates with survival of HCC patients after sorafenib therapy［J］. JCI Insight, 2016, 1(11):e86182.

［4］Cabrera R, Ararat M, Xu Y, et al. Immune modulation of effector CD4+ and regulatory T cell function by sorafenib in patients with hepatocellular carcinoma［J］. Cancer Immunol Immunother, 2013, 62(4):737-746.

［5］Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial［J］. Lancet Oncol, 2009, 10(1):25-34.

［6］Chen J, Jin R, Zhao J, et al. Potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma［J］. Cancer Lett, 2015, 367(1):1-11.

［7］Zhang XM, Chen FH, Huang XY, et al. Culture and identification of fibroblast-like synoviocytes from rat with adjuvant arthritis in vitro［J］. Chinese Journal of Anatomy, 2007, 30(6):770-773.(in Chinese)

张晓明, 陈飞虎, 黄学应, 等. 佐剂性关节炎大鼠成纤维样滑膜细胞的体外培养与鉴定［J］. 解剖学杂志, 2007, 30(6):770-773.

［8］Yang Y. Methotrexate in the treatment of rheumatoid arthritis［J］. Tianjin Pharmacy, 2009, 21(4):58-61.(in Chinese)

杨媛. 甲氨蝶呤在治疗类风湿性关节炎的应用［J］. 天津药学, 2009, 21(4):58-61.

［9］Wilhelm SM, Adnane L, Newell P, et al. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling［J］. Mol Cancer Ther, 2008, 7(10):3129-3140.

［10］Yan W, Gao J, Di Z, et al. New insights into the antifibrotic effects of sorafenib on hepatic stellate cells and liver fibrosis［J］. J Hepatol, 2010, 53(1):132-144.

［11］Zahavi T, Lanton T, Divon MS, et al. Sorafenib treatment during partial hepatectomy reduces tumorgenesis in an inflammation-associated liver cancer model［J］. Oncotarget, 2015, 7(4):4860-4870.

［12］Ren GH, Huang W, Xiao X, et al. Effects of oxymatrine on joint inflammation and T cell subsets in rats with collagen induced arthritis［J］. Chinese Pharmaceutical Journal, 2012, 47(5):350-353.(in Chinese)

任广慧, 黄伟, 肖旭, 等. 氧化苦参碱对胶原蛋白诱导大鼠关节炎症及T细胞亚群的影响［J］. 中国药学杂志, 2012, 47(5):350-353.

［13］Zhang Y, Lü Y, Lü TT, et al. Elevated circulating Th17 and follicular helper CD4+ T cells in patients with rheumatoid arthritis［J］. Apmis, 2015, 123(8):659-666.

［14］Bai ST, Chen PH, Chen YY, et al. Ethyl acetate extract from celastrus aculeatus Merr. Suppresses synovial inflammation in adjuvant arthritis rats through apoptosis induction of CD4(+)CD25(+)FOXP3(+) T Cells［J］. Evid Based Complement Alternat Med, 2014, 2014:460136.

［15］Lin XD, Qi YL, Chen ShQ, et al. Clinical significance of thrombospondin-4 expression in gastric carcinoma［J］. Acta Anatomica Sinica, 2010, 41(1):65-69.(in Chinese)

林贤东, 齐元麟, 陈淑勤, 等. 血小板反应素-4在胃癌中的表达及其临床意义［J］. 解剖学报, 2010, 41(1):65-69.

［16］Huang XY, Zhang XM, Chen FH, et al. Anti-proliferative effect of recombinant human endostatin on synovial fibroblasts in rats with adjuvant arthritis［J］. Eur J Pharmacol, 2014, 723(1):7-14.

［17］Fournier C. Where do T cells stand in rheumatoid arthritis ［J］? Joint Bone Spine, 2005, 72(6):527-532.

［18］Roberts CA, Dickinson AK, Taams LS. The Interplay between monocytes/macrophages and CD4(+) T cell subsets in rheumatoid arthritis［J］. Front Immunol, 2015, 6(3):571-590.［19］Guo M, An G, Feng GY, et al. The research development of CD4+T cell subset in rheumatoid arthritis［J］. Chinese Journal of Cellular and Molecular Immunology, 2014, 30(9):1004-1007.(in Chinese)

郭明, 安高, 封桂英, 等. CD4+T细胞亚群在类风湿性关节炎中的研究进展［J］. 细胞与分子免疫学杂志, 2014, 30(9):1004-1007.

［20］Scrivo R, Di Franco M, Spadaro A, et al. The immunology of rheumatoid arthritis［J］. Ann N Y Acad Sci, 2007, 1108(1):312-322.

［21］Cope AP, Schulze-Koops H, Aringer M. The central role of T cells in rheumatoid arthritis［J］. Clin Exp Rheumatol, 2007, 25(5 Suppl 46):S4-11.

［22］Ma L, Simpson E, Li J, et al. CD8+ T cells are predominantly protective and required for effective steroid therapy in murine models of immune thrombocytopenia［J］. Blood, 2015, 126(2):247-256.

［23］Jung YO, Min SY, Cho ML, et al. CD8alpha+ dendritic cells enhance the antigen-specific CD4+ T-cell response and accelerate development of collagen-induced arthritis［J］. Immunol Lett, 2007, 111(2):76-83.

［24］Cho YG, Cho ML, Min SY, et al. Type II collagen autoimmunity in a mouse model of human rheumatoid arthritis［J］. Autoimmun Rev, 2007, 7(7):65-70.

［25］Koch AE. The role of angiogenesis in rheumatoid arthritis: recent developments［J］. Ann Rheum Dis, 2000, 59(Suppl 1):i65-i71.

［26］Elshabrawy HA, Chen Z, Volin MV, et al. The pathogenic role of angiogenesis in rheumatoid arthritis［J］. Angiogenesis, 2015, 18(4):433-448.